Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc.RARE · Entity 4337 | See Remarks | April 16, 2026 | April 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ultragenyx Pharmaceutical Inc.
Report date April 16, 2026 · Filed April 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 147,845 |
Reported balance
After 2026-04-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-04-16 · Grant · Acquired 23,116 · Balance 147,845 F1: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date F2: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.52 · Expires 2036-04-16 | Direct | 79,936 |
Reported balance
After 2026-04-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-16 · Grant · Acquired 79,936 · Balance 79,936 F3: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. |
Filing footnotes · ownership attribution and instrument terms
F1: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date
F2: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
F3: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 16, 2026 Filed Apr 20, 2026 21:17 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 79,936 | $0.00 Strike: $24.52 | $0.00 |
DisclosureSEC source: 0001193125-26-164297 · ownership.xml · derivative · entry 2 Huang Dennis Karl · CIK 0001641217 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,936 Underlying: Common Stock · 79,936 shares Expires 2036-04-16 F3 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. Read SEC document |
| April 16, 2026 Filed Apr 20, 2026 21:17 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 23,116 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-164297 · ownership.xml · nonDerivative · entry 1 Huang Dennis Karl · CIK 0001641217 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 147,845 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 23:49 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 999 | $23.39 | $23,366.61 |
DisclosureSEC source: 0001193125-26-089102 · ownership.xml · nonDerivative · entry 2 Huang Dennis Karl · CIK 0001641217 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 124,729 F2 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs. F3 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 23:49 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 11,137 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-089102 · ownership.xml · nonDerivative · entry 1 Huang Dennis Karl · CIK 0001641217 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,728 F1 · shares: Represents shares of common stock which previously granted performance stock units were converted on March 1, 2026 upon certification of the performance metric. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 01:02 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 1,348 | $42.92 | $57,856.16 |
DisclosureSEC source: 0000950170-25-032767 · ownership.xml · nonDerivative · entry 3 Huang Dennis Karl · CIK 0001641217 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,591 F3 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs. F4 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 01, 2025 Filed Mar 5, 2025 01:02 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 26,074 | $0.00 Strike: $42.92 | $0.00 |
DisclosureSEC source: 0000950170-25-032767 · ownership.xml · derivative · entry 4 Huang Dennis Karl · CIK 0001641217 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,074 Underlying: Common Stock · 26,074 shares Expires 2035-03-01 F5 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. Read SEC document |
| March 01, 2025 Filed Mar 5, 2025 01:02 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 18,443 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-032767 · ownership.xml · nonDerivative · entry 2 Huang Dennis Karl · CIK 0001641217 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,939 F2 · shares: Represents shares of common stock which previously granted performance stock units were converted on March 1, 2025 upon certification of the performance metric. Read SEC document |
| March 01, 2025 Filed Mar 5, 2025 01:02 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 14,494 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-032767 · ownership.xml · nonDerivative · entry 1 Huang Dennis Karl · CIK 0001641217 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,496 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 01:17 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 31,400 | $0.00 Strike: $53.69 | $0.00 |
DisclosureSEC source: 0000950170-24-026652 · ownership.xml · derivative · entry 4 Huang Dennis Karl · CIK 0001641217 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,400 Underlying: Common Stock · 31,400 shares Expires 2034-03-01 F5 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 01:17 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 470 | $53.69 | $25,234.30 |
DisclosureSEC source: 0000950170-24-026652 · ownership.xml · nonDerivative · entry 3 Huang Dennis Karl · CIK 0001641217 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,002 F3 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs. F4 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 01:17 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 957 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-026652 · ownership.xml · nonDerivative · entry 2 Huang Dennis Karl · CIK 0001641217 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,472 F2 · shares: Represents shares of common stock which previously granted performance stock units were converted on March 1, 2024 upon certification of the performance metric. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 01:17 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 17,800 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-026652 · ownership.xml · nonDerivative · entry 1 Huang Dennis Karl · CIK 0001641217 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,515 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date Read SEC document |
| March 01, 2023 Filed Mar 4, 2023 00:53 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 39,400 | $0.00 Strike: $45.65 | $0.00 |
DisclosureSEC source: 0001209191-23-016043 · doc4.xml · derivative · entry 5 Huang Dennis Karl · CIK 0001641217 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,400 Underlying: Common Stock · 39,400 shares Expires 2033-03-01 F6 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. Read SEC document |
| March 01, 2023 Filed Mar 4, 2023 00:53 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Disposition to issuerCommon Stock | 10,599 | $45.65 | $483,844.35 |
DisclosureSEC source: 0001209191-23-016043 · doc4.xml · nonDerivative · entry 4 Huang Dennis Karl · CIK 0001641217 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,715 F4 · shares: Shares were acquired upon the partial vesting of a previously reported RSU and were sold to permit the cash value of the awards to be credited to the deferred compensation plan account of the Reporting Person. F5 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 01, 2023 Filed Mar 4, 2023 00:53 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 389 | $45.65 | $17,757.85 |
DisclosureSEC source: 0001209191-23-016043 · doc4.xml · nonDerivative · entry 3 Huang Dennis Karl · CIK 0001641217 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,314 F3 · shares: Represents shares sold to pay required tax withholdings due to the vesting of RSUs. Read SEC document |
| March 01, 2023 Filed Mar 4, 2023 00:53 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 22,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016043 · doc4.xml · nonDerivative · entry 2 Huang Dennis Karl · CIK 0001641217 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,703 F2 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date. Read SEC document |
| March 01, 2023 Filed Mar 4, 2023 00:53 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 2,663 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016043 · doc4.xml · nonDerivative · entry 1 Huang Dennis Karl · CIK 0001641217 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,703 F1 · shares: Represents shares of common stock which previously granted performance stock units were converted on March 1, 2023 upon certification of the performance metric. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 23:09 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 24,900 | $0.00 Strike: $67.37 | $0.00 |
DisclosureSEC source: 0001209191-22-015815 · doc4.xml · derivative · entry 3 Huang Dennis Karl · CIK 0001641217 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,900 Underlying: Common Stock · 24,900 shares Expires 2032-03-01 F5 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 23:09 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 14,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-015815 · doc4.xml · nonDerivative · entry 2 Huang Dennis Karl · CIK 0001641217 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,040 F2 · shares: Award of RSUs under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date. F3 · balance_after: Includes 126 shares acquired under the Company's 2014 Employee Stock Purchase Plan on October 29, 2021. F4 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 23:09 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 3,234 | $66.62 | $215,449.08 |
DisclosureSEC source: 0001209191-22-015815 · doc4.xml · nonDerivative · entry 1 Huang Dennis Karl · CIK 0001641217 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,914 F1 · kind: Represents shares sold to pay required tax withholdings due to the vesting of Restricted Stock Units ("RSUs"). Read SEC document |
| October 14, 2021 Filed Oct 18, 2021 22:55 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 358 | $81.14 | $29,048.12 |
DisclosureSEC source: 0001209191-21-060759 · doc4.xml · nonDerivative · entry 1 Huang Dennis Karl · CIK 0001641217 · EVP & Chief Tech Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,148 F1 · kind: Represents shares sold by the Reporting Person to pay required tax withholdings due to the vesting of Restricted Stock Units ("RSUs"). F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| May 06, 2021 Filed May 10, 2021 22:14 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 363 | $113.68 | $41,265.84 |
DisclosureSEC source: 0001209191-21-031390 · doc4.xml · nonDerivative · entry 1 Huang Dennis Karl · CIK 0001641217 · EVP & Chief Tech Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,506 F1 · kind: Represents shares sold to pay required tax withholdings due to the vesting of RSUs. F2 · balance_after: Includes 108 shares acquired under the Company's 2014 Employee Stock Purchase Plan on April 30, 2021. F3 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:39 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 11,000 | $0.00 Strike: $142.47 | $0.00 |
DisclosureSEC source: 0001209191-21-017546 · doc4.xml · derivative · entry 4 Huang Dennis Karl · CIK 0001641217 · EVP & Chief Tech Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2031-03-01 F7 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:39 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 4,255 | $138.18 | $587,955.90 |
DisclosureSEC source: 0001209191-21-017546 · doc4.xml · nonDerivative · entry 3 Huang Dennis Karl · CIK 0001641217 · EVP & Chief Tech Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,761 F3 · kind: Represents shares sold to pay required tax withholdings due to the vesting of RSUs. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $138.17 to $138.19 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F5 · balance_after: Includes 181 shares acquired under the Company's 2014 Employee Stock Purchase Plan on October 31, 2020. F6 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:39 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 4,636 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-017546 · doc4.xml · nonDerivative · entry 2 Huang Dennis Karl · CIK 0001641217 · EVP & Chief Tech Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,835 F2 · shares: Represents 1,530 shares of common stock and 3,106 RSUs into which previously granted performance stock units were converted on March 1, 2021 upon certification of the performance metric. The RSUs will fully vest on March 1, 2022. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:39 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 5,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-017546 · doc4.xml · nonDerivative · entry 1 Huang Dennis Karl · CIK 0001641217 · EVP & Chief Tech Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,199 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date. Read SEC document |
| October 14, 2020 Filed Oct 16, 2020 23:18 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 262 | $88.00 | $23,056.00 |
DisclosureSEC source: 0001209191-20-055174 · doc4.xml · nonDerivative · entry 1 Huang Dennis Karl · CIK 0001641217 · EVP & Chief Tech Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,699 F1 · shares: Represents shares sold to pay required tax withholdings due to the vesting of Restricted Stock Units ("RSUs"). F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 18:21 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 262 | $69.38 | $18,177.56 |
DisclosureSEC source: 0001209191-20-033888 · doc4.xml · nonDerivative · entry 1 Huang Dennis Karl · CIK 0001641217 · EVP & Chief Tech Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,961 F1 · shares: Represents shares sold to pay required tax withholdings due to the vesting of Restricted Stock Units ("RSUs"). F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. F3 · balance_after: Includes 244 shares acquired under the Company's 2014 Employee Stock Purchase Plan on April 30, 2020. Read SEC document |
| May 06, 2020 Filed May 9, 2020 00:10 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 248 | $66.26 | $16,432.48 |
DisclosureSEC source: 0001209191-20-028116 · doc4.xml · nonDerivative · entry 1 Huang Dennis Karl · CIK 0001641217 · EVP & Chief Tech Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,979 F1 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of Restricted Stock Units ("RSUs"). F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| April 19, 2020 Filed Apr 21, 2020 19:32 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 248 | $58.57 | $14,525.36 |
DisclosureSEC source: 0001209191-20-025187 · doc4.xml · nonDerivative · entry 1 Huang Dennis Karl · CIK 0001641217 · EVP & Chief Tech Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,227 F1 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of Restricted Stock Units ("RSUs"). F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 01, 2020 Filed Mar 4, 2020 00:55 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 22,000 | $0.00 Strike: $56.08 | $0.00 |
DisclosureSEC source: 0001209191-20-015752 · doc4.xml · derivative · entry 4 Huang Dennis Karl · CIK 0001641217 · EVP & Chief Tech Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2030-03-01 F6 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. Read SEC document |
| March 01, 2020 Filed Mar 4, 2020 00:55 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 1,779 | $56.08 | $99,766.32 |
DisclosureSEC source: 0001209191-20-015752 · doc4.xml · nonDerivative · entry 3 Huang Dennis Karl · CIK 0001641217 · EVP & Chief Tech Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,475 F4 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. F5 · balance_after: Includes 241 shares acquired under the Company's 2014 Employee Stock Purchase Plan on October 31, 2019. Read SEC document |
| March 01, 2020 Filed Mar 4, 2020 00:55 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 5,634 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-015752 · doc4.xml · nonDerivative · entry 2 Huang Dennis Karl · CIK 0001641217 · EVP & Chief Tech Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,013 F3 · shares: Represents 1,859 shares of common stock and 3,775 RSUs into which previously granted performance stock units were converted on March 1, 2020 upon certification of the performance metric. The RSUs will fully vest on March 1, 2021. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 01, 2020 Filed Mar 4, 2020 00:55 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 7,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-015752 · doc4.xml · nonDerivative · entry 1 Huang Dennis Karl · CIK 0001641217 · EVP & Chief Tech Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,379 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| October 14, 2019 Filed Oct 16, 2019 23:31 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 1,434 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-053327 · doc4.xml · nonDerivative · entry 1 Huang Dennis Karl · CIK 0001641217 · EVP & Chief Tech Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,579 F1 · shares: Represents restricted stock units (RSUs) into which previously granted performance stock units were converted on October 14, 2019 upon certification of the applicable performance metric. Half of these RSUs will vest on the first anniversary of the certification date and the other half will vest on the second anniversary of the certification date. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| June 01, 2019 Filed Jun 4, 2019 22:51 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 260 | $54.93 | $14,281.80 |
DisclosureSEC source: 0001209191-19-034543 · doc4.xml · nonDerivative · entry 1 Huang Dennis Karl · CIK 0001641217 · EVP & Chief Tech Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,145 F1 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| May 06, 2019 Filed May 7, 2019 22:48 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 1,434 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-028085 · doc4.xml · nonDerivative · entry 2 Huang Dennis Karl · CIK 0001641217 · EVP & Chief Tech Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,405 F4 · shares: Represents restricted stock units (RSUs) into which previously granted performance stock units were converted on May 6, 2019 upon certification of the applicable performance metric. Half of these RSUs will vest on the first anniversary of the certification date and the other half will vest on the second anniversary of the certification date. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. F3 · balance_after: Includes 175 shares acquired under the Company's 2014 Employee Stock Purchase Plan on April 30, 2019. Read SEC document |
| May 05, 2019 Filed May 7, 2019 22:48 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 649 | $67.99 | $44,125.51 |
DisclosureSEC source: 0001209191-19-028085 · doc4.xml · nonDerivative · entry 1 Huang Dennis Karl · CIK 0001641217 · EVP & Chief Tech Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,971 F1 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. F3 · balance_after: Includes 175 shares acquired under the Company's 2014 Employee Stock Purchase Plan on April 30, 2019. Read SEC document |
| April 19, 2019 Filed Apr 23, 2019 22:36 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 248 | $64.43 | $15,978.64 |
DisclosureSEC source: 0001209191-19-025618 · doc4.xml · nonDerivative · entry 1 Huang Dennis Karl · CIK 0001641217 · EVP & Chief Tech Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,445 F1 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 05, 2019 Filed Apr 17, 2019 21:58 UTC Amendment | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 626 | $65.52 | $41,015.52 |
DisclosureSEC source: 0001209191-19-025114 · doc4a.xml · nonDerivative · entry 2 Huang Dennis Karl · CIK 0001641217 · EVP & Chief Tech Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,693 F4 · shares: Represents shares sold to pay required tax withholdings due to the vesting of Restricted Stock Units. Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 22:12 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $67.55 | $0.00 |
DisclosureSEC source: 0001209191-19-015750 · doc4.xml · derivative · entry 3 Huang Dennis Karl · CIK 0001641217 · EVP & Chief Tech Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-03-01 F5 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 22:12 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 607 | $67.55 | $41,002.85 |
DisclosureSEC source: 0001209191-19-015750 · doc4.xml · nonDerivative · entry 2 Huang Dennis Karl · CIK 0001641217 · EVP & Chief Tech Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,711 F4 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs. Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 22:12 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-015750 · doc4.xml · nonDerivative · entry 1 Huang Dennis Karl · CIK 0001641217 · EVP & Chief Tech Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,318 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. F3 · balance_after: Includes 194 shares acquired under the Company's 2014 Employee Stock Purchase Plan. Read SEC document |
| March 01, 2019 Filed Apr 17, 2019 21:58 UTC Amendment | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $67.55 | $0.00 |
DisclosureSEC source: 0001209191-19-025114 · doc4a.xml · derivative · entry 3 Huang Dennis Karl · CIK 0001641217 · EVP & Chief Tech Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-03-01 F5 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. Read SEC document |
| March 01, 2019 Filed Apr 17, 2019 21:58 UTC Amendment | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-025114 · doc4a.xml · nonDerivative · entry 1 Huang Dennis Karl · CIK 0001641217 · EVP & Chief Tech Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,319 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. F3 · balance_after: Includes 194 shares acquired under the Company's 2014 Employee Stock Purchase Plan. Read SEC document |
| June 01, 2018 Filed Jun 4, 2018 20:52 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 260 | $73.73 | $19,169.80 |
DisclosureSEC source: 0001209191-18-035189 · doc4.xml · nonDerivative · entry 1 Huang Dennis Karl · CIK 0001641217 · EVP & Chief Tech Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,124 F1 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| May 05, 2018 Filed May 8, 2018 21:44 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 649 | $54.50 | $35,370.50 |
DisclosureSEC source: 0001209191-18-028672 · doc4.xml · nonDerivative · entry 1 Huang Dennis Karl · CIK 0001641217 · EVP & Chief Tech Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,384 F1 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs. F2 · balance_after: Includes 183 shares acquired under the Company's 2014 Employee Stock Purchase Plan on April 30, 2018. F3 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| April 19, 2018 Filed Apr 19, 2018 20:48 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 1,431 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-025596 · doc4.xml · nonDerivative · entry 1 Huang Dennis Karl · CIK 0001641217 · EVP & Chief Tech Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,850 F1 · shares: Represents restricted stock units (RSUs) into which previously granted performance stock units were converted on April 19, 2018 upon certification of the applicable performance metric. Half of these RSUs will vest on the first anniversary of the certification date and the other half will vest on the second anniversary of the certification date. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:23 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $48.43 | $0.00 |
DisclosureSEC source: 0001209191-18-016446 · doc4.xml · derivative · entry 3 Huang Dennis Karl · CIK 0001641217 · EVP & Chief Tech Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-03-01 F5 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:23 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 205 | $48.43 | $9,928.15 |
DisclosureSEC source: 0001209191-18-016446 · doc4.xml · nonDerivative · entry 2 Huang Dennis Karl · CIK 0001641217 · EVP & Chief Tech Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,419 F4 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.